Novartis, BeiGene lay out frontline PhIII data for PD-1 drug as second-line PDUFA date looms

Paul Schloesser

Associate Editor

As the FDA prepares to decide on Novartis and BeiGene’s PD-1 drug tislelizumab in the second-line setting, the pair is already preparing for its potential …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis, BeiGene lay out frontline PhIII data for PD-1 drug as second-line PDUFA date looms

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

No­var­tis, BeiGene lay out front­line PhI­II da­ta for PD-1 drug as sec­ond-line PDU­FA date looms

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Novartis, BeiGene lay out frontline PhIII data for PD-1 drug as second-line PDUFA date looms

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?